Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
Tianzhou YuShihan JinChang LiJames D ChambersJakub P HlávkaPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2023)
Our study offered novel insights on the factors associated with biosimilar coverage by commercial health plans in the US relative to their reference products. Cancer treatment, pediatric population, and coverage restriction of the reference products are some of the most significant factors that are associated with biosimilar coverage decisions.